Shares of Juniper Pharmaceuticals, Inc. (NASDAQ:JNP) have been assigned an average recommendation of “Hold” from the six analysts that are covering the company, MarketBeat.com reports. Three investment analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $23.00.

JNP has been the subject of a number of research reports. Roth Capital set a $12.00 price objective on shares of Juniper Pharmaceuticals and gave the stock a “buy” rating in a research note on Saturday, May 6th. ValuEngine lowered shares of Juniper Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. HC Wainwright reaffirmed a “hold” rating on shares of Juniper Pharmaceuticals in a research note on Monday, May 15th. Finally, BMO Capital Markets raised shares of Juniper Pharmaceuticals from a “market perform” rating to an “outperform” rating and upped their price objective for the stock from $31.00 to $34.00 in a research note on Friday, July 14th.

Juniper Pharmaceuticals (NASDAQ:JNP) traded down 4.81% during midday trading on Friday, hitting $4.45. 28,080 shares of the stock traded hands. The firm’s 50-day moving average is $4.95 and its 200-day moving average is $4.73. The company has a market cap of $48.26 million, a price-to-earnings ratio of 5.75 and a beta of 0.28. Juniper Pharmaceuticals has a 52-week low of $3.65 and a 52-week high of $7.15.

Juniper Pharmaceuticals (NASDAQ:JNP) last released its quarterly earnings data on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.03) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.13) by $0.10. Juniper Pharmaceuticals had a net margin of 13.94% and a return on equity of 21.49%. The company had revenue of $13.96 million during the quarter, compared to analyst estimates of $11.84 million. Analysts predict that Juniper Pharmaceuticals will post ($0.51) EPS for the current year.

Institutional investors have recently modified their holdings of the company. JW Asset Management LLC increased its position in shares of Juniper Pharmaceuticals by 10.0% in the second quarter. JW Asset Management LLC now owns 426,903 shares of the specialty pharmaceutical company’s stock valued at $2,156,000 after buying an additional 38,771 shares during the period. Algert Global LLC increased its position in shares of Juniper Pharmaceuticals by 10.8% in the second quarter. Algert Global LLC now owns 120,035 shares of the specialty pharmaceutical company’s stock valued at $606,000 after buying an additional 11,720 shares during the period. Spark Investment Management LLC increased its position in shares of Juniper Pharmaceuticals by 33.0% in the second quarter. Spark Investment Management LLC now owns 60,000 shares of the specialty pharmaceutical company’s stock valued at $303,000 after buying an additional 14,900 shares during the period. Municipal Employees Retirement System of Michigan acquired a new position in shares of Juniper Pharmaceuticals during the second quarter valued at $1,192,000. Finally, Acadian Asset Management LLC increased its position in shares of Juniper Pharmaceuticals by 2.3% in the second quarter. Acadian Asset Management LLC now owns 41,978 shares of the specialty pharmaceutical company’s stock valued at $211,000 after buying an additional 941 shares during the period. Institutional investors own 36.75% of the company’s stock.

WARNING: “Juniper Pharmaceuticals, Inc. (JNP) Receives Consensus Rating of “Hold” from Brokerages” was first reported by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another website, it was copied illegally and reposted in violation of international copyright legislation. The original version of this article can be read at https://www.americanbankingnews.com/2017/08/12/juniper-pharmaceuticals-inc-jnp-receives-consensus-rating-of-hold-from-brokerages.html.

Juniper Pharmaceuticals Company Profile

Juniper Pharmaceuticals, Inc is a women’s health therapeutics company. The Company is focused on developing therapeutics that address unmet medical needs in women’s health. It operates in two segments: product and service. The product segment is engaged in manufacturing and supplying CRINONE, the Company’s commercialized product.

Receive News & Ratings for Juniper Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juniper Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.